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To determine the efficacy of potential cystic fibrosis (CF) therapies we have developed a novel mucociliary
transit (MCT) measurement that uses synchrotron phase contrast X-ray imaging (PCXI) to non-invasively
measure the transit rate of individual micron-sized particles deposited into the airways of livemice. The aim
of this study was to image changes inMCT produced by a rehydrating treatment based on hypertonic saline
(HS), a current CF clinical treatment. Live mice received HS containing a long acting epithelial sodium
channel blocker (P308); isotonic saline; or no treatment, using a nebuliser integrated within a small-animal
ventilator circuit. Marker particle motion was tracked for 20 minutes using PCXI. There were statistically
significant increases in MCT in the isotonic and HS-P308 groups. The ability to quantify in vivo changes in
MCT may have utility in pre-clinical research studies designed to bring new genetic and pharmaceutical
treatments for respiratory diseases into clinical trials.
M
ucociliary transport (MCT) requires the coordinated beating of cilia, microscopic hair-like structures, to
propel the airway surface liquid (ASL) across the surfaces of epithelial cells. This integrated activity
provides the primary method for removing deposited pathogens and particulates from airway surfaces.
In cystic fibrosis (CF), a dysfunctional CF transmembrane conductance regulator (CFTR) ion channel in airway
epithelial cells results in dehydration of the ASL and impaired MCT. The MCT failure produces retention of
inhaled pathogens and particulates, mucus obstruction, chronic infection, and eventually lung failure1. Current
clinical assessments of CF airway disease and its treatment are indirect. A logical method to assess the effect of CF
treatments on airway surfaces is to directly measure restoration of MCT activity by tracking the movement of
depositedmarker particles along the airways. The ability to directly visualise deposited particleMCT behaviour in
live animal model airways could provide spatio-temporal information pertaining to the initiation and mainten-
ance of CF pathophysiology and potentially reveal novel directions for the development of preventative therapies
for CF airway disease.
To determine the efficacy of genetic2,3 and other potential therapies for CF airway disease in animal models,
with a view to ultimate use in humans, we have developed a novel MCTmonitoring method based on measuring
the transit rate and behaviour of individual particles deposited in the lungs using synchrotron phase contrast X-
ray imaging (PCXI). This technique can be used in vivo in live anaesthetisedmice4–6. By comparison, conventional
in vivoMCTmeasurement methods rely on measuring bulk particle clearance from the airways7–10, are unable to
track the motion of individual micron sized deposited particles with high spatial or temporal resolution, and
cannot be used to assess spatial or temporal variations in MCT homogeneity within the airways.
An alternative method to accurately track individual particle MCT involves the use of an ex vivo system. A recent
study examined the transit of individual deposited particles of dried ink in an ex vivo porcine system, and
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showed that treatment with hypertonic saline restored MCT in only
half of the ex vivo porcine tracheas they tested, but that surface active
substances provided additional benefits in restoration of MCT.
However, the obvious limitation of these systems is the requirement
for tissue excision and support in an artificial environment. We
propose that direct, non-invasive visualisation of individual depos-
ited particle MCT in live intact animal-model airways should: (1)
improve our understanding of airway health and disease and (2)
allow the effects of therapeutic agents on MCT to be rapidly and
accurately quantified.
PCXI can produce enhanced soft tissue contrast even when the
absorption differences are small by utilising X-ray refraction in addi-
tion to conventional absorption. Provided the X-ray beam is spatially
coherent, increasing the sample to detector distance13–15 enhances
tissue boundaries due to the phase changes that are induced by
differences in the tissue X-ray refractive indices. We have reported
on the benefits of PCXI for non-invasive airspace imaging in small
animals16, for non-invasive particulate detection in live mouse air-
ways4–6,17, and for the visualisation and assessment of surrogate fluid
dosing regimes for airway gene therapy treatments in live mice18,19.
Our previous studies also examined theMCT behaviour of a range of
common pollutant particles delivered to the airways in either a saline
carrier fluid5,6 or as a dry powder4. These studies revealed that depos-
ited lead dust, typically ranging from 5 mm up to 12 mm diameter
and with a small number of larger particles present (see Figure 3 in
Donnelley, Siu, et al.5), was a suitable marker for analysing tracheal
MCT behaviour via PCXI. Furthermore, this technique also permits
long-term repeated-measure study designs to assess treatments with-
out animal sacrifice.
The aims of this study were to non-invasively observe the basal
surface mucus transport activity of live mouse airways, at micron
resolution, and to image and quantify changes in particle MCT pro-
duced by a rehydrating treatment for CF airways disease, i.e. inhaled
hypertonic saline (HS) combined with a long acting epithelial
sodium channel (ENaC) blocker (P308). HS acutely increases
MCT in both CF and normal patients by directly increasing the
osmotic load on the airway surface and triggering a water flux onto
the airway surface. In CF this response can help rehydrate the airway
surface and improve airway clearance20. The ENaC channel is upre-
gulated in CF and further increases the ASL dehydration produced
by the CFTR dysfunction, so any compound that inhibits the action
of the ENaC channel should increase epithelial hydration. In this
study the combined HS-P308 treatment was used to maximise this
rehydration effect, thereby producing a large change in MCT.
Although the effects of rehydrating treatments such as HS on
MCT have previously been observed in excised sections of airway
epithelium12, they have never been examined or quantified in intact
airways in vivo.
Results
Experiments were performed at the SPring-8 synchrotron radiation
facility in Japan. Lead marker particles were delivered to the airways
of live anaesthetized and intubated mice, prior to PCXI. Mice (n 5 5
per group) were randomly assigned to a no treatment control group,
an isotonic saline aerosol control group, or the HS-P308 aerosol
treatment group. Images were captured prior to, during and after
aerosol delivery, and all particle movement was tracked to determine
the MCT rate.
Assessment of the MCT rate of a large number of particles was
chosen as a reliable indicator of the immediate effectiveness of iso-
tonic saline orHS-P308 to alter airwayMCT rates. For the 12 animals
successfully studied (aerosol delivery failed in one animal from the
isotonic group, and two from the HS-P308 group), the mean time
between dry particle insufflation and initiation of the imaging run
was 5 minutes. Deposited lead particles were immediately visible in
the trachea of all animals when imaging began, but the majority were
stationary for the first two imaging periods (i.e. during baseline, prior
to aerosol delivery). The MCT rate rapidly increased within the
aerosol delivery period. However, the particle transit was heterogen-
eous: that is, some particles did not move while others transited the
field of view rapidly. In addition, as previously reported4–6, many
particles followed unpredictable and non-linear paths along the air-
way. An example of this motion is shown in Figure 3 and in the
Supplementary Video.
A total of 11,743 individual particle MCT measurements were
made for the 12 mice in the study. Figure 4 shows that the MCT rate
was increased in the isotonic saline and HS-P308 treatment groups
compared to theNoRxControl group at all post delivery time points.
TheMCT rate of theNoRxControl groupwas 0.276 0.11 mm/min.
Isotonic saline produced a more pronounced early (5.5 min) effect
than HS-308, but the effect of HS-P308 was sustained and greater in
magnitude at the later time points. Specifically, at the 5.5 min time-
point the isotonic MCT rate was statistically higher than the HS-
P308 group, whereas at the 13.5 min time-point the HS-P308 MCT
Figure 1 | The synchrotron in vivo PCXI setup.Mice are held supine on an x-y-rotation stage in the BL20XU imaging hutch, 245 m from the undulator
X-ray source. A propagation distance of 1 m was used.
www.nature.com/scientificreports
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rate was significantly higher than the isotonic group. A total of 335
particles (i.e. ,3% of the total number of particles tracked) were
excluded from the analysis based on the chosen maximum-speed
criteria, with a significantly greater number of particles excluded
from theHS-P308 group than the isotonic group (P, 0.05, unpaired
t-test). These results show that delivery of aerosolised fluid increased
theMCT rate compared to control/baseline, regardless of the tonicity
of the fluid. However, the initiation and duration ofMCT effects after
aerosol treatment differed with treatment.
The complex airway surfaceMCT particlemovements are difficult
to adequately describe and difficult to represent in static images (See
Fig. 3), so the Supplementary Video should be viewed to reveal the
nature of particle movements and to enable dynamic visual compar-
ison of the effects of the isotonic saline and HS-P308 aerosols with
the control group. The rapid onset of the effects of isotonic saline and
the durable effect of HS-P308 are clearly visible in this comparison
video. Note that in these X-ray image sequences all particle activities
on both (lateral) tracheal walls are superimposed, so it is not possible
to determine which tracheal wall surface (i.e. the near or the far wall)
the particulates are located on. In addition, some particulates and
particulate motion appears to be located below the apparent tracheal
edge. As previously reported4, this phenomenon is due to the v
shaped dorsal wall of the trachea formed by an epithelial protrusion
in the dorsal surface of the trachea into the lumen.
Discussion
This study has demonstrated that aerosolised fluid increased the
mean MCT rate of individual particles deposited onto the tracheal
airway surface compared to a control group, and that HS-P308, a CF
airway-hydrating therapy, produced a more sustained increase in
MCT rate compared to isotonic saline. Importantly, these findings
show for the first time that it is possible to directly compare the
effects of pharmaceutical treatments on individual particle MCT in
mice in vivo.
The basal rates of transit measured in this study were lower than
those reported by Grubb et al.7 who used a dye-transit technique and
reported that bulk mouse tracheal MCT was 2.2 6 0.45 (SE) mm/
min. Via comparisons to other studies, Grubb et al. also noted that
the recorded MCT rate was heavily influenced by the marker size/
type used. The lead particles used in the present study may be
Figure 2 | The experimental imaging plan. Images were acquired in 30 second blocks (green bars, top panel) every twominutes at a rate of one image per
breath (2 Hz). After two baseline imaging periods the aerosol (purple, lower panel) was delivered for 2.5 min. Imaging continued for a further ,18
minutes.
Figure 3 | Typical PCXI image showing the result from manual particle
tracking at one imaging period. The mouse is supine with the lungs to the
left and the mouth to the right; MCT is primarily in a left-to-right
direction. The first frame (marked in green) from a sequence of 10 is shown
with the location of tracked particles in the following framesmarked with a
red dot. Note that particle motion is not homogeneous; some particles
move long distances, some short distances, and some (unmarked,
primarily along the dorsal tracheal surface) remain stationary over those
10 frames.
Figure 4 | Effect of therapeutics onMCT. TheMCT rate was calculated by
manually tracking the movement of up to 50 particles across 10 frames at
each time point in each mouse. MCT rates are presented as mean and
standard error of the mean X+SE
 
. Statistical significance was set at p 5
0.05 and power 5 0.80 and MCT rates were analysed by two way RM-
ANOVA with Bonferroni multiple comparisons. The difference in MCT
rate between the Isotonic and HS-P308 group at the 5.5 and 13.5 min time
points was statistically significant (**p , 0.01 and *** p , 0.001).
www.nature.com/scientificreports
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handled by the MCT system in a different manner to either fluor-
escent dyes7 or ink particles11, both of which are much smaller and
lighter. However, in a previous lead marker particle study we
recorded a tracheal MCT rate of 1.82 6 1.6 mm/min4, a rate that
was substantially higher than what we recorded in this study. We
hypothesise that the absence of an inspiratory humidification system
in this study may have resulted in dehydration of the airway surface
by the dry imaging hutch air used to ventilate the animals, resulting
in slower baseline and control MCT rates.
The effects of isotonic saline on accelerating MCT were rapid, i.e.,
peaked at 5.5 min, but were short-lived.We speculate that the initial,
rapid effect was mediated by rehydrating the ventilator-induced
dehydrated airway surface, with restoration of MCT. However, the
effect of isotonic saline was relatively short lived because the added
volume was rapidly absorbed by the epithelium by an ENaC
mediated Na1 absorption mechanism21,22. In contrast, the effect of
HS-P308 on MCT exhibited the opposite pattern, i.e., a moderate
early effect (5.5 min) with a more robust delayed (15.5 min) res-
ponse. Two possible explanations could account for the moderation
of the early response. First, it has been reported that amiloride blocks
aquaporin mediated transepithelial water flow in response to
imposed osmotic gradients23. However, the newer and more highly
potent ENaC blockers, such as P308, do not appear to exhibit an
aquaporin block activity24. Second, it has been reported that rapid
delivery of HS can overwhelm the ability of transepithelial water flow
to buffer ASL hypertonicity following rapid aerosolization of HS25.
The consequence is loss of water from epithelial cells into the lumen,
cell shrinkage, reduction in cilial beat frequency, and slowed MCT.
Although we favour the latter explanation, studies of HS vs. P308
alone will be required to rigorously test this possibility. With respect
to the larger ‘‘delayed’’ increase in MCT following HS-P308 vs. iso-
tonic saline, it is likely the extended duration reflects the block of
ENaC mediated absorption of the salt deposited on aerosol surfaces
via aerosolization. Thus, the liquid added to the tracheal surface
added in response to aerosolized HS-P308 remained on the tracheal
surface for prolonged periods.
Our study provides unique details into the mode of clearance of
particles from the trachea. As seen in the Supplementary Movie,
particles in the aerosol treated groups continually moved up from
deeper in the lungs, into the trachea, suggesting that the insufflation
technique dosed lung regions distal to the delivery site. Although we
observed particle movement throughout the imaging period, the
particulates were not expected to be completely cleared from the
imaged airway region over this short imaging period. However, as
noted above, the data shows that an aerosol treatment can increase
the particle clearance rate when compared to baseline. In all animals,
there were particles that remained immobile, likely due to their cap-
ture within the periciliary layer and/or persistent adherent mucus.
This finding shows that changes in MCT activity produced by rehy-
dration are heterogeneous and that rehydration of adherent mucus
may not be rapid. The failure to mobilize all particles suggests that
studiesmust be directed towards understanding this phenomena and
how to address it therapeutically. Conversely, there were many part-
icles that moved much more rapidly throughout the imaging period,
with amaximum particle MCT rate of 140 mm/min recorded. These
high rates typically resulted from cough-like respiratory movements
(as suggested by transient spikes in airway pressure; data not shown),
or rapid bulk fluid movements, and so were excluded from the stat-
istical analyses.
This study had several limitations. The primary limitation was the
small number of mice in the aerosol treatment groups, a direct result
of the limited beam-time allocation (a total of 48 hours including
experimental setup) available at the SPring-8 synchrotron. In future
studies, the effects of MCT altering therapeutics in larger groups of
mice, including distinguishing the effects of HS alone (since HS is
already used as a CF clinical treatment) from the P308 ENaC blocker
will be studied. Similarly, the effects of using a humidification cham-
ber in the ventilator inspiratory line on the measured MCT will also
be quantified. Tracking particles for extended periods (longer than
20 minutes) should also further distinguish the effects of HS and
P308. Future studies may also use tracking particles with improved
characteristics. The relatively large size of lead particles and the lack
of particle surface uniformity likely affected theMCT rates observed.
However, the marker particles must be of the appropriate size and X-
ray density to be detectable in vivo by PCXI, and a dispersion of sizes
may mimic real environmental exposures. Finally, it is also possible
that the requirement for manual tracking of the deposited particles
resulted in observer bias. We minimised this effect by blinding the
observer to the treatments. However, we have begun to develop new
visual analytical techniques to better address this particle tracking
issue.
In summary, this study has shown that the effects of therapeutics
thought to restore the MCT rate can be directly quantified using
synchrotron PCXI. Moreover, this technique can be readily applied
to assessing MCT at any appropriate time-point within lung clear-
ance studies, to test the effects of a variety of pharmaceutical treat-
ments in appropriate mouse model strains. We are continuing our
efforts to improve our direct and non-invasive MCT imaging assess-
ment methods to assist our understanding and treatment of respir-
atory diseases such as CF.
Methods
Ethics statement. Experiments were performed on the BL20XU undulator beamline
at the SPring-8 synchrotron radiation facility in Japan, under approvals from the
Animal Ethics Committees of SPring-8, the Women’s and Children’s Health
Network, and the University of Adelaide.
Imaging setup. The experimental hutch was located in the Biomedical Imaging
Centre, 245 metres from the storage ring (see Fig. 1). Monochromatic 25 keV
(l 5 0.5A˚) X-rays were selected using a standard double-crystal monochromator26.
A propagation (sample to detector) distance of ,1 m was used as in previous
experiments4. Images were captured using a high-resolution X-ray converter (SPring-
8 BM3) with a sCMOS detector. The converter used a 10 mm thick scintillator
(Lu2SiO5:Ce) to convert X-rays to visible light, which was then directed to the sCMOS
sensor using a 310 microscope objective lens (NA 0.45). The sCMOS detector was a
pco.edge (PCO Imaging) with an array size of 25603 2160 pixels and a 6.5 3 6.5 mm
native pixel size. This setup resulted in an effective isotropic pixel size of 0.56 mm and
a field of view of 1.43 mm3 1.2 mm. The incident beamwas limited to this size using
slits to reduce the radiation dose to the animals. Image capture was synchronised with
a fast shutter (Uniblitz XRS6 with VMM-T1 timer unit) and triggered by the
ventilator (refer to animal preparation description below) to minimise the dose
between exposures. An exposure length of 10 ms was optimal for producing a high
SNR without movement blur.
Animal preparation.Mice (n 5 15, C57Bl/6, weight,18–20 grams) were prepared
as for previous experiments27. Briefly, mice were anaesthetized with pentobarbital
(Somnopentil, Pitman-Moore, Washington Crossing, USA; 100 mg/kg i.p.) and
intubated using a fibre-optic illuminated guide wire and a 20 Ga i.v. catheter (Insyte,
Becton Dickinson, Utah, USA) as an endotracheal (ET) tube28. The ET tube was
inserted into the trachea to a fixed depth of 22.5 mm from the nose tip. This location
placed the ET tube tip approximately half way between the epiglottis and the carina to
avoid physically perturbing the more distal imaging region. The fur around the
imaging area was removed using surgical clippers (CareFusion, San Diego, USA;
Neuro blade) followed by depilatory cream (Nair, Church &Dwight, Australia). After
intubation a small quantity (less than 0.001 g) of lead dust was delivered to the
trachea and lungs using a Dry Powder InsufflatorTM Model DP-4M (Penn-Century,
Wyndmoor, PA, USA). The particle size distribution was as previously described4.
Due to high variability in the output (particle mass) of the first actuation of the air
pump, the first output was discarded and the second actuation was used to deliver the
sample to the airways. The insufflator was thoroughly cleaned with compressed air
between deliveries to remove any residual particles prior to reloading.
Mice were tethered to an imaging board with their dorsal incisors hooked over a
stainless-steel wire loop and the limbs, and their shoulders and torso were taped to the
board to minimise body movements that interfere with high-resolution imaging.
The imaging board was mounted on the hutch sample stage so that the mouse was
oriented supine and the X-ray beam passed laterally through the mouse trachea,
approximately five cartilage rings distal to the tip of the ET tube. Anaesthesia was
maintained throughout the experiment by constant pentobarbital infusion
(0.1 mg/kg/sec) via an indwelling i.p. needle attached to a micro-syringe pump
(UltraMicroPump III and Micro4 controller, World Precision Instruments, Florida,
USA). The ET tube was attached to a flexiVent small animal ventilator (SCIREQ,
Montreal, Canada), and ventilation was set at 120 breaths/min, a tidal volume of
www.nature.com/scientificreports
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15 ml/kg (minute ventilation of approximately 1.8 ml/g), and ,3 cmH2O of PEEP.
The flexiVent provided a trigger to capture a single image during each end-expiratory
pause. Body temperature was maintained using an infrared heat lamp.
Aerosol treatment and imaging. Mice were randomly assigned to one of three
groups; a no treatment control group (No Rx Control, n 5 5); an isotonic saline
control group (n 5 4); or the treatment group (n 5 3). Mice in the treatment group
(HS-P308) received compound P308 (Parion Sciences, Durham, NC, USA), a potent
and long acting epithelial sodium channel (ENaC) blocker, at a concentration of
1 mM, in 7%HS to produce themaximal rehydrating effect. One image was captured
per breath (2 Hz) for a 30 second period every 2 min (see Fig. 2) to reduce radiation
dose and maintain shutter performance. After two imaging periods were obtained to
calculate the baseline MCT rate prior to treatment, the aerosol was delivered for
2.5 min using an Aeroneb nebuliser (Aerogen, Ireland) designed to produce a 4–
6 mm volume median diameter aerosol. The Aeroneb was attached to the ventilator
inspiratory line, and the flexiVent controlled aerosol delivery to occur at a 50% duty
cycle during inspiration only. Imaging continued for a further,20 minutes (a total of
11 time-points) before mice were humanely killed via Nembutal overdose without
waking from anaesthesia.
Post experimental analyses. All images were flat-field and dark-current corrected
(Matlab R2012b, The Mathworks, Natick, MA, USA). Changes in image brightness
produced by the inherent instability of the X-ray beam (manifested primarily as
flicker caused by rapid changes in the vertical position of the beam over time) were
minimised using a flicker-reduction algorithm that normalised the intensity of each
row of pixels in the image.
Individual particle MCT rates were quantified using a Matlab program that pre-
sented an observer with 10 frames (from one imaging period) over which particle
motion was to be tracked. For the treatment groups the 10 frames were sequential (i.e.
every breath). For the control group and all baseline measurements every fifth frame
was used to improve tracking accuracy at slow particle MCT rates. The observer was
then asked to manually track the location of a chosen particle in each of those 10
frames. The 10 frame sequence was then presented again, this time with the location
of the previously tracked particle(s) shown, and the observer was asked to track
another particle. This process was repeated until a maximum of 50 particles were
tracked, or no further moving particles could be identified in the sequence. The
analysis then proceeded to the next imaging period (see Fig. 2), until all 11 periods
were analysed. This whole cycle was repeated for each animal, with the observer
blinded to any information that would identify the treatment that an animal had
received, thereby preventing observer bias.
The distance that each particle moved between each of the 10 frames was calculated
in pixels and converted to millimetres based on the size of the field of view. TheMCT
rate was then calculated (in mm/min) based on the time between analysis frames.
Particles moving faster than 15 mm/min (chosen based on previous studies11,12) were
excluded from further analysis because these likely resulted from ‘cough-like’
movements or rapid bulk fluidmovements. AmeanMCT rate was calculated for each
time-point in every animal. Statistical analyses were performed using GraphPad
Prism 5. Data were tested for normality, statistical significance was set at p5 0.05 and
power 5 0.80 and MCT rates were analysed by two way RM-ANOVA with
Bonferroni multiple comparisons. MCT rates are presented as mean and standard
error of the mean X+SE
 
.
Images were created to show the motion of tracked particles at each time-point. A
supplementary movie file (.avi format) was also assembled from the processed post-
deposition images to compare particulate behaviour on the tracheal airway surface in
the three groups. The movie frame rate was set to 53 normal speed, was encoded
using the Xvid codec and can be played using the free VLCMedia Player (available at
http://www.videolan.org/vlc/).
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